PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics (Alternext: ALEHT) (Paris:ALEHT) confirms its intention to complete an external growth transaction in the US, in the field of molecular diagnostics, during the third quarter of 2010. This objective was communicated several times by the Company, during its financing in December 2009 and, more recently, on March 10, 2010, while reporting its 2009 annual results and its 2010 outlook.
